ABT vs EDIT · P/E 25, rev $44.33B vs rev $32.3M
Abbott Laboratories (ABT) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the ABT and EDIT stock pages for the full models.
Not investment advice.